Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet

Stock News

昨天

Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a "Drug Clinical Trial Approval Notice" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).

The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).

According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1147997181"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147997181\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147997181?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147997181","market":"us","top_or_hot":-1,"title":"Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet","media":"Stock News","content":"<p><b>Beijing Centergate Technologies (Holding) Co., Ltd.</b> has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).<br><br>The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).<br><br>According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentergate Subsidiary Gains Clinical Trial Clearance for Methylphenidate Prolonged-Release Chewable Tablet\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-09-01 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Beijing Centergate Technologies (Holding) Co., Ltd.</b> has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).<br><br>The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).<br><br>According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000931","symbol_name":"中關村","start_time":0,"source_url":"","article_id":"1147997181","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147997181","pubTimestamp":1788253380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"000931":"中关村","BK0239":"医药制造","BK0028":"国家队","BK0075":"新三板","BK0178":"特色小镇","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","PSYK":"PSYK ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF"},"translate_title":"Centergate子公司获得哌醋甲酯缓释咀嚼片临床试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1,"BMED":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"PSYK":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a \"Drug Clinical Trial Approval Notice\" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}